In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma
Oncotarget · 2025
DOI: 10.18632/oncotarget.28764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncotarget, 2025. Verfasst von Kristen Kwong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA 94143, USA. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Proteostasis, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
The protein homeostasis (proteostasis) network includes quality control systems that coordinate protein synthesis, folding, localization, and degradation, and is deregulated in numerous diseases including cancer. Loss of proteostasis can activate lethal cellular stress responses, potentially opening a therapeutic window. Previous research demonstrated that MAL3-101, an inhibitor of heat shock protein 70-kD (HSP70) chaperones, selectively induces rhabdomyosarcoma (RMS) cell death via unfolded protein response (UPR) activation. RMS is the most common pediatric soft tissue sarcoma, and relapsed patients are rarely cured despite transient responses to DNA-damaging therapy. To examine whether MAL3-101 or more drug-like proteostasis inhibitors represent a new therapeutic strategy for RMS, we screened proteostasis components that might recapitulate the effects of MAL3-101 in vivo. We find that inhibition of VCP, which encodes the p97 ATPase that facilitates proteasome-dependent degradation, similarly activates the UPR and induces RMS apoptosis. In mouse models, a preclinical p97 inhibitor showed superior bioavailability and anti-tumor activity compared to MAL3-101. Patient-derived xenografts exhibited a spectrum of p97 inhibitor sensitivities, and RNA sequencing of resistant tumors revealed elevated autophagy, nominating a biomarker of proteostasis adaptability. Together, these findings confirm that proteostasis inhibition can slow RMS growth and suggest that targeting compensatory network components might yield synergistic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA 94143, USA.
- Department of Pediatrics, Georgetown University, Washington, DC 20057, USA.
- Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA 94143, USA.
- Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
- Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA.
- Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Förderung
- NIDDK NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
Zitieren
APA
Kwong, K., Pan, Y., Morales, J., Watson, M., Allegakoen, D. V., Lee, A. G., Bivona, T. G., Wipf, P., Guerriero, C. J., Brodsky, J. L., & Sabnis, A. J. (2025). In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma. Oncotarget. https://doi.org/10.18632/oncotarget.28764
Vancouver
Kwong K, Pan Y, Morales J, Watson M, Allegakoen DV, Lee AG, et al. In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma. Oncotarget. 2025. doi:10.18632/oncotarget.28764
BibTeX
@article{Kwong2025,
author = {Kwong, Kristen and Pan, Yue and Morales, Jacqueline and Watson, Matthew and Allegakoen, David V and Lee, Alex G and Bivona, Trever G and Wipf, Peter and Guerriero, Christopher J and Brodsky, Jeffrey L and Sabnis, Amit J},
title = {In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma},
journal = {Oncotarget},
year = {2025},
doi = {10.18632/oncotarget.28764}
}
EUVIMED